home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 04/09/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - Lessons On Delayed Response Trading Expectations From GFI, CYDY, And CAPR

source: Investopedia I've recently been trading a lot of stocks associated with the COVID-19 pandemic, as well as gold stocks, as their volatility make for great opportunities to generate some serious profits quickly, based upon the rapid movement of the share price. While these moveme...
CYDY - Kiniksa's Unexpected Play

Preface: We believe most pre-commercial biotechs do not trade like traditional stocks, being largely event-driven. Hence, our approach focuses heavily on the science and much less so on the financials. Of course, metrics such as cash burn and debt are important and do inform our decision mak...

CYDY - Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7

VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

CYDY - Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn's Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab and Disc

VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - CytoDyn And COVID-19

CytoDyn's ( CYDY ) high-energy CEO Nadir Pourhassan [NP] has been in his element in the fast-paced news cycle attendant upon all things COVID-19. Today, as I write on 4/7/20, he has responded to both a Charles Payne Fox Business interview along with another in his series of regular Proactiv...

CYDY - Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn's Leronlimab

VANCOUVER, Washington and WINSTON-SALEM, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeut...

CYDY - "Next Super Stock" Conference Presenters Making News: CytoDyn (OTC: CYDY) New Coronavirus Treatment Progress. NexTech AR Solutions (OTC: NEXCF): Analyst Coverage; Remote Work/Learning Acquisition, Revenue Accelerates. FaceBank Group (OTC: FBNK) Completes

NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting companies which recently presented at its NEXT SUPER STOCK livestream investor conference series which are making news headlines this week. Wall Street Report...
CYDY - FDA Allows Expanded Use Of Remote Devices To Monitor Patients' Vital Signs In Global COVID-19 Health Crisis

April 7, 2020 Palm Beach, FL – April 7, 2020 – As the global health crisis quickly spreads in the United States, officials face the daunting task of treating patients in person and monitoring their progress. With quarantines increasing throughout the world, healthca...

CYDY - CytoDyn teams up with U.K.'s Department of Health for leronlimab in COVID-19 patients

CytoDyn ( OTCQB:CYDY ) is collaborating with the U.K.’s Department of Health to provide emergency access to leronlimab, an investigational medicine for COVID-19. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - CytoDyn Collaborating with U.K.'s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients

VANCOUVER, Washington, April 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
Previous 10 Next 10